OACC vs RLAY vs BCTX vs RXRX vs NUVL

For growth investors, Relay Therapeutics, Inc.

(RLAY) is the stronger pick with 53. 4% revenue growth year-over-year, versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). Oaktree Acquisition Corp. III Life Sciences (OACC) offers the better valuation at 195. 8x trailing P/E, making it the more compelling value choice. Analysts rate Relay Therapeutics, Inc. (RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Nuvalent, Inc.

(NUVL) delivered a total return of +446. 1%, compared to -99. 2% for BriaCell Therapeutics Corp. (BCTX). Over 10 years, the gap is even starker: NUVL returned +446. 1% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.

III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 3817% more volatile than OACC relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 7% for Recursion Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Relay Therapeutics, Inc.

(RLAY) is pulling ahead at 53. 4% versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). On earnings-per-share growth, the picture is similar: Relay Therapeutics, Inc. grew EPS 31. 8% year-over-year, compared to -48. 9% for Nuvalent, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Oaktree Acquisition Corp.

III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — RLAY leads at 76. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Oaktree Acquisition Corp.

III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OACC: +6. 1%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (OACC (Financial Services) and RLAY (Healthcare) and BCTX (Healthcare) and RXRX (Healthcare) and NUVL (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: OACC is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock; BCTX is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; NUVL is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.